<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744651</url>
  </required_header>
  <id_info>
    <org_study_id>Endodrill III</org_study_id>
    <nct_id>NCT02744651</nct_id>
  </id_info>
  <brief_title>EUS-Endodrill vs. EUS-FNA for Diagnosis of Submucosal Tumors in the Upper GI Tract</brief_title>
  <official_title>EUS-Endodrill vs. EUS-FNA for Diagnosis of Submucosal Tumors in the Upper GI Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endodrill is a new instrument for biopsy sampling in the GI-channel. The purpose of this
      study is as follows:

      - Compare EUS-guided Endodrill biopsies with endoscopic ultrasound guided fine needle
      aspiration (EUS-FNA) in terms of ability to establish the correct diagnosis of submucosal
      tumors in the upper GI tract.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endodrill is a newly constructed biopsy tool for flexible endoscopic use. It uses a drilling
      motion within a casing to harvest solid biopsies from tissue through the biopsy channel of a
      conventional flexible endoscope. It was originally designed for sampling of tissue from
      submucosal lesions. The investigators first study of the instrument is now finished.
      Endodrill is safe to use and generates more submucosal tissue compared to biopsies with a
      conventional biopsy forceps.

      In this study the investigators want to compare the Endodrill instrument with FNA (both
      modalities EUS-guided) in terms of ability to obtain the correct diagnosis of submucosal
      tumors in the upper GI-tract. Patients diagnosed with suspected submucosal tumors in the
      upper GI-tract will be enrolled to this study. They will first go through examination with
      EUS. If the suspicion of a submucosal tumor is confirmed, the investigator will perform both
      EUS guided FNA and Endodrill biopsies in the same patient.The harvested tissue will be
      evaluated by senior pathologists to clarify which method that generates most correct
      diagnosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of correct histopathological diagnoses from submucosal tumors in the upper GI tract.</measure>
    <time_frame>24 months</time_frame>
    <description>Number of biopsies with the correct histopathological diagnoses</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gastrointestinal Neoplasms</condition>
  <arm_group>
    <arm_group_label>EUS-FNA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients with a confirmed suspicion of a submucosal tumor in the upper GI tract will be included in this study. A senior endoscopist will perform multiple passes of EUS-FNA until she/he has collected enough material for the pathologist to establish a possible diagnosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EUS-Endodrill biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients who are included in the study will also be examined by a senior endoscopist performing multiple EUS guided passes with the Endodrill biopsy. The harvested tissue from the tumor will be examined by a pathologist in order to establish a diagnosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EUS-FNA</intervention_name>
    <description>Please note the text in section &quot;Arm description&quot;</description>
    <arm_group_label>EUS-FNA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EUS-Endodrill biopsy</intervention_name>
    <description>Please note the text in section &quot;Arm description&quot;</description>
    <arm_group_label>EUS-Endodrill biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with a suspected submucosal tumor in the upper GI tract that are
             available for both EUS-guided FNA and Endodrill biopsy

        Exclusion Criteria:

          -  Mental illness

          -  Extreme co-morbidity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Johansson, SrConsultant</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Sk√•ne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin J Jeremiasen, Consultant</last_name>
    <phone>+46-70-3304950</phone>
    <email>martin.jeremiasen@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan Johansson, SrConsultant</last_name>
    <phone>+46-46-171000</phone>
    <email>jan.johansson@med.lu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Lund</name>
      <address>
        <city>Lund</city>
        <state>Skane</state>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin j Jeremiasen, MD</last_name>
      <phone>+46-70-3304950</phone>
      <email>martin.jeremiasen@med.lu.se</email>
    </contact>
    <contact_backup>
      <last_name>Jan Johansson, MD</last_name>
      <phone>+46-46-171432</phone>
      <email>jan.johansson@med.lu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 5, 2016</study_first_submitted>
  <study_first_submitted_qc>April 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Region Skane</investigator_affiliation>
    <investigator_full_name>Martin Jeremiasen</investigator_full_name>
    <investigator_title>Consultant Surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

